Interleukin-10: Potential Benefits and Possible Risks in Clinical Infectious Diseases
Human interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of the major proinflammatory cytokines and chemokines. IL-10 is the principal TH2-type cytokine that upregulates humoral immune responses and attenuates cell-mediated immune reactions. This cytokine has a...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 1998-12, Vol.27 (6), p.1497-1507 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1507 |
|---|---|
| container_issue | 6 |
| container_start_page | 1497 |
| container_title | Clinical infectious diseases |
| container_volume | 27 |
| creator | Opal, Steven M. Wherry, Janice C. Grint, Paul |
| description | Human interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of the major proinflammatory cytokines and chemokines. IL-10 is the principal TH2-type cytokine that upregulates humoral immune responses and attenuates cell-mediated immune reactions. This cytokine has a number of immunomodulatory properties that might be clinically useful in a variety of inflammatory and infectious disease states. Clinical trials with human recombinant IL-10 are already in progress. Carefully selected patients with inflammatory conditions may benefit from IL- 10 therapy if concomitant infectious diseases are recognized and treated appropriately. |
| doi_str_mv | 10.1086/515032 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69098774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4481755</jstor_id><sourcerecordid>4481755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-af66af4fbf1bc9bead5e9256f1014a2c8663e3698d95cc2a030e74f1dc6333fe3</originalsourceid><addsrcrecordid>eNpFkF1LHDEUhkOpWLX1F1iYi-Ld1GTyMUnv7Kp1QWgpKuJNyGROIO5sVnOyUP99I7usVwl5Ht6c8xJyzOh3RrU6k0xS3n0gB0zyvlXSsI_1TqVuheb6EzlEfKKUMU3lPtk3Wmml-gNyN08F8gTrRUwtoz-aP6sCqUQ3NT8hQYgFG5fG-owYhwmavxEX2MTUzKaYoq_ePAXwJa7W2FxEBIeAn8lecBPCl-15RO6uLm9n1-3N71_z2flN67kRpXVBKRdEGAIbvBnAjRJMJ1VglAnX-ToiB66MHo30vnOUU-hFYKNXnPMA_IicbnKf8-plDVjsMqKHaXIJ6jxWGWp034t30ee6SIZgn3NcuvxqGbVv_dlNf1X8uk1cD0sYd9q2sMq_bbnDunzILvmI72mKKdPzqp1stCcsq7zDQmjWS1lxu8ERC_zbYZcXtv7RS3v98GhnwnSK319Ywf8DUmuOuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69098774</pqid></control><display><type>article</type><title>Interleukin-10: Potential Benefits and Possible Risks in Clinical Infectious Diseases</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>JSTOR</source><source>EZB Electronic Journals Library</source><creator>Opal, Steven M. ; Wherry, Janice C. ; Grint, Paul</creator><creatorcontrib>Opal, Steven M. ; Wherry, Janice C. ; Grint, Paul</creatorcontrib><description>Human interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of the major proinflammatory cytokines and chemokines. IL-10 is the principal TH2-type cytokine that upregulates humoral immune responses and attenuates cell-mediated immune reactions. This cytokine has a number of immunomodulatory properties that might be clinically useful in a variety of inflammatory and infectious disease states. Clinical trials with human recombinant IL-10 are already in progress. Carefully selected patients with inflammatory conditions may benefit from IL- 10 therapy if concomitant infectious diseases are recognized and treated appropriately.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/515032</identifier><identifier>PMID: 9868667</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antiinflammatories ; B lymphocytes ; Biological and medical sciences ; Communicable Diseases - drug therapy ; Cytokines ; Endotoxemia - drug therapy ; Endotoxins ; Humans ; Immunomodulators ; Infections ; Infectious diseases ; Interleukin-10 - therapeutic use ; Medical sciences ; Mice ; Monocytes ; Pharmacology. Drug treatments ; Receptors ; Receptors, Interleukin - biosynthesis ; Receptors, Interleukin-10 ; Review Article ; T lymphocytes</subject><ispartof>Clinical infectious diseases, 1998-12, Vol.27 (6), p.1497-1507</ispartof><rights>Copyright 1998 The Infectious Diseases Society of America</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-af66af4fbf1bc9bead5e9256f1014a2c8663e3698d95cc2a030e74f1dc6333fe3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4481755$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4481755$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1616973$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9868667$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Opal, Steven M.</creatorcontrib><creatorcontrib>Wherry, Janice C.</creatorcontrib><creatorcontrib>Grint, Paul</creatorcontrib><title>Interleukin-10: Potential Benefits and Possible Risks in Clinical Infectious Diseases</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Human interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of the major proinflammatory cytokines and chemokines. IL-10 is the principal TH2-type cytokine that upregulates humoral immune responses and attenuates cell-mediated immune reactions. This cytokine has a number of immunomodulatory properties that might be clinically useful in a variety of inflammatory and infectious disease states. Clinical trials with human recombinant IL-10 are already in progress. Carefully selected patients with inflammatory conditions may benefit from IL- 10 therapy if concomitant infectious diseases are recognized and treated appropriately.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antiinflammatories</subject><subject>B lymphocytes</subject><subject>Biological and medical sciences</subject><subject>Communicable Diseases - drug therapy</subject><subject>Cytokines</subject><subject>Endotoxemia - drug therapy</subject><subject>Endotoxins</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interleukin-10 - therapeutic use</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Monocytes</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors</subject><subject>Receptors, Interleukin - biosynthesis</subject><subject>Receptors, Interleukin-10</subject><subject>Review Article</subject><subject>T lymphocytes</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkF1LHDEUhkOpWLX1F1iYi-Ld1GTyMUnv7Kp1QWgpKuJNyGROIO5sVnOyUP99I7usVwl5Ht6c8xJyzOh3RrU6k0xS3n0gB0zyvlXSsI_1TqVuheb6EzlEfKKUMU3lPtk3Wmml-gNyN08F8gTrRUwtoz-aP6sCqUQ3NT8hQYgFG5fG-owYhwmavxEX2MTUzKaYoq_ePAXwJa7W2FxEBIeAn8lecBPCl-15RO6uLm9n1-3N71_z2flN67kRpXVBKRdEGAIbvBnAjRJMJ1VglAnX-ToiB66MHo30vnOUU-hFYKNXnPMA_IicbnKf8-plDVjsMqKHaXIJ6jxWGWp034t30ee6SIZgn3NcuvxqGbVv_dlNf1X8uk1cD0sYd9q2sMq_bbnDunzILvmI72mKKdPzqp1stCcsq7zDQmjWS1lxu8ERC_zbYZcXtv7RS3v98GhnwnSK319Ywf8DUmuOuw</recordid><startdate>19981201</startdate><enddate>19981201</enddate><creator>Opal, Steven M.</creator><creator>Wherry, Janice C.</creator><creator>Grint, Paul</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981201</creationdate><title>Interleukin-10: Potential Benefits and Possible Risks in Clinical Infectious Diseases</title><author>Opal, Steven M. ; Wherry, Janice C. ; Grint, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-af66af4fbf1bc9bead5e9256f1014a2c8663e3698d95cc2a030e74f1dc6333fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antiinflammatories</topic><topic>B lymphocytes</topic><topic>Biological and medical sciences</topic><topic>Communicable Diseases - drug therapy</topic><topic>Cytokines</topic><topic>Endotoxemia - drug therapy</topic><topic>Endotoxins</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interleukin-10 - therapeutic use</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Monocytes</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors</topic><topic>Receptors, Interleukin - biosynthesis</topic><topic>Receptors, Interleukin-10</topic><topic>Review Article</topic><topic>T lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Opal, Steven M.</creatorcontrib><creatorcontrib>Wherry, Janice C.</creatorcontrib><creatorcontrib>Grint, Paul</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Opal, Steven M.</au><au>Wherry, Janice C.</au><au>Grint, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-10: Potential Benefits and Possible Risks in Clinical Infectious Diseases</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1998-12-01</date><risdate>1998</risdate><volume>27</volume><issue>6</issue><spage>1497</spage><epage>1507</epage><pages>1497-1507</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Human interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of the major proinflammatory cytokines and chemokines. IL-10 is the principal TH2-type cytokine that upregulates humoral immune responses and attenuates cell-mediated immune reactions. This cytokine has a number of immunomodulatory properties that might be clinically useful in a variety of inflammatory and infectious disease states. Clinical trials with human recombinant IL-10 are already in progress. Carefully selected patients with inflammatory conditions may benefit from IL- 10 therapy if concomitant infectious diseases are recognized and treated appropriately.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>9868667</pmid><doi>10.1086/515032</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 1998-12, Vol.27 (6), p.1497-1507 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69098774 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; JSTOR; EZB Electronic Journals Library |
| subjects | Adjuvants, Immunologic - therapeutic use Animals Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antiinflammatories B lymphocytes Biological and medical sciences Communicable Diseases - drug therapy Cytokines Endotoxemia - drug therapy Endotoxins Humans Immunomodulators Infections Infectious diseases Interleukin-10 - therapeutic use Medical sciences Mice Monocytes Pharmacology. Drug treatments Receptors Receptors, Interleukin - biosynthesis Receptors, Interleukin-10 Review Article T lymphocytes |
| title | Interleukin-10: Potential Benefits and Possible Risks in Clinical Infectious Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T18%3A58%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-10:%20Potential%20Benefits%20and%20Possible%20Risks%20in%20Clinical%20Infectious%20Diseases&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Opal,%20Steven%20M.&rft.date=1998-12-01&rft.volume=27&rft.issue=6&rft.spage=1497&rft.epage=1507&rft.pages=1497-1507&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/515032&rft_dat=%3Cjstor_proqu%3E4481755%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69098774&rft_id=info:pmid/9868667&rft_jstor_id=4481755&rfr_iscdi=true |